Bolt Biotherapeutics (BOLT)
Market Price (2/15/2026): $5.06 | Market Cap: $9.7 MilSector: Health Care | Industry: Biotechnology
Bolt Biotherapeutics (BOLT)
Market Price (2/15/2026): $5.06Market Cap: $9.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -88% | Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -149% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -860% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -25% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -47% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 56% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -907%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -907% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -453% | ||
| Key risksBOLT key risks include [1] a strategic pivot to a high-risk, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -88% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -25% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -149% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -860% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -47% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 56% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -907%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -907% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -453% |
| Key risksBOLT key risks include [1] a strategic pivot to a high-risk, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bolt Biotherapeutics (BOLT) stock has lost about 15% since 10/31/2025 because of the following key factors:
1. Delayed Clinical Data for Key Pipeline Candidate BDC-4182
Bolt Biotherapeutics announced on October 1, 2025, that initial clinical data for its BDC-4182 Phase 1 dose escalation study would be delayed until the third quarter of 2026. This postponement of results for a significant clinical candidate likely contributed to investor uncertainty and a negative stock reaction, as it pushed back a potential catalyst for the company's valuation.
2. Significant Workforce Reduction to Conserve Capital
In conjunction with the clinical trial update for BDC-4182, Bolt Biotherapeutics also disclosed a substantial workforce reduction of approximately 50%. While implemented to conserve capital and extend the company's cash runway into 2027, such a drastic measure often signals financial distress or a restructuring of priorities, which can be viewed unfavorably by the market.
Show more
1. Delayed Clinical Data for Key Pipeline Candidate BDC-4182
Bolt Biotherapeutics announced on October 1, 2025, that initial clinical data for its BDC-4182 Phase 1 dose escalation study would be delayed until the third quarter of 2026. This postponement of results for a significant clinical candidate likely contributed to investor uncertainty and a negative stock reaction, as it pushed back a potential catalyst for the company's valuation.
2. Significant Workforce Reduction to Conserve Capital
In conjunction with the clinical trial update for BDC-4182, Bolt Biotherapeutics also disclosed a substantial workforce reduction of approximately 50%. While implemented to conserve capital and extend the company's cash runway into 2027, such a drastic measure often signals financial distress or a restructuring of priorities, which can be viewed unfavorably by the market.
Show more
Stock Movement Drivers
Fundamental Drivers
The -12.2% change in BOLT stock from 10/31/2025 to 2/15/2026 was primarily driven by a -29.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.76 | 5.06 | -12.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 24.7% |
| P/S Multiple | 2.7 | 1.9 | -29.5% |
| Shares Outstanding (Mil) | 2 | 2 | -0.1% |
| Cumulative Contribution | -12.2% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BOLT | -14.1% | |
| Market (SPY) | -0.0% | 26.1% |
| Sector (XLV) | 9.3% | 3.0% |
Fundamental Drivers
The -10.4% change in BOLT stock from 7/31/2025 to 2/15/2026 was primarily driven by a -37.2% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.65 | 5.06 | -10.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 42.8% |
| P/S Multiple | 3.0 | 1.9 | -37.2% |
| Shares Outstanding (Mil) | 2 | 2 | -0.1% |
| Cumulative Contribution | -10.4% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BOLT | -12.4% | |
| Market (SPY) | 8.2% | 21.0% |
| Sector (XLV) | 21.4% | 6.6% |
Fundamental Drivers
The -48.4% change in BOLT stock from 1/31/2025 to 2/15/2026 was primarily driven by a -46.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.80 | 5.06 | -48.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 5 | -46.9% |
| P/S Multiple | 1.9 | 1.9 | -2.5% |
| Shares Outstanding (Mil) | 2 | 2 | -0.4% |
| Cumulative Contribution | -48.4% |
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BOLT | -49.5% | |
| Market (SPY) | 14.3% | 29.0% |
| Sector (XLV) | 8.8% | 27.4% |
Fundamental Drivers
The -82.8% change in BOLT stock from 1/31/2023 to 2/15/2026 was primarily driven by a -83.6% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.40 | 5.06 | -82.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | 7.6% |
| P/S Multiple | 11.4 | 1.9 | -83.6% |
| Shares Outstanding (Mil) | 2 | 2 | -2.4% |
| Cumulative Contribution | -82.8% |
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BOLT | -83.2% | |
| Market (SPY) | 74.0% | 21.3% |
| Sector (XLV) | 23.7% | 19.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BOLT Return | -85% | -73% | -14% | -52% | -49% | -10% | -99% |
| Peers Return | -27% | -43% | -6% | -9% | 21% | 13% | -50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| BOLT Win Rate | 27% | 33% | 50% | 25% | 25% | 50% | |
| Peers Win Rate | 38% | 38% | 42% | 53% | 55% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BOLT Max Drawdown | -87% | -74% | -34% | -55% | -58% | -10% | |
| Peers Max Drawdown | -34% | -68% | -46% | -34% | -45% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, ZYME, ADCT, MGNX, STRO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | BOLT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.9% | -25.4% |
| % Gain to Breakeven | 4581.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to GILD, ZYME, ADCT, MGNX, STRO
In The Past
Bolt Biotherapeutics's stock fell -97.9% during the 2022 Inflation Shock from a high on 3/17/2021. A -97.9% loss requires a 4581.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
AI Analysis | Feedback
1. Like **Seagen (now Pfizer)**, a leader in Antibody-Drug Conjugates (ADCs), but instead of delivering chemotherapy, Bolt Biotherapeutics aims to deliver immune-stimulating drugs directly to cancer cells.
2. A targeted immunotherapy company, similar in goal to **Merck's Keytruda** or **Bristol Myers Squibb's Opdivo**, but delivering immune activators directly to tumors via antibodies rather than broadly modulating the immune system.
AI Analysis | Feedback
- BNT141 (formerly BOLT-141): An immune-stimulating antibody conjugate (ISAC) targeting HER2-positive solid tumors, developed in collaboration with BioNTech.
- BNT142 (formerly BOLT-142): An immune-stimulating antibody conjugate (ISAC) targeting Claudin18.2-positive tumors, also developed in collaboration with BioNTech.
- Boltbodyâ„¢ ISAC Platform: A proprietary technology platform designed to develop immune-stimulating antibody conjugates that activate innate and adaptive immunity against solid tumors.
AI Analysis | Feedback
Bolt Biotherapeutics (BOLT) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies. As is typical for companies in this stage of development, it does not sell products directly to individuals. Its primary revenue streams are derived from strategic collaboration and licensing agreements with larger pharmaceutical companies.
Based on their public filings, Bolt Biotherapeutics' major customers/partners that contribute to its revenue are:
- Bristol Myers Squibb Company (Symbol: BMY)
- Genmab A/S (Symbol: GMAB)
AI Analysis | Feedback
null
AI Analysis | Feedback
Willie Quinn, Chief Executive Officer
Appointed CEO in May 2020, Mr. Quinn joined Bolt Biotherapeutics in 2020. Prior to Bolt, he served as Chief Financial Officer and Senior Vice President of Corporate Development at Sunesis Pharmaceuticals (acquired by Viracta Therapeutics), where he led the company through multiple public financings and corporate collaborations. He also co-founded and was Chief Executive Officer of Bullet Biotechnology, an immuno-oncology company. Earlier in his career, Mr. Quinn was instrumental in establishing the infrastructure at Jazz Pharmaceuticals and served as Chief Financial Officer and Chief Operating Officer of Novation Biosciences (acquired by Agilent Technologies).
Sarah Nemec, SVP, Finance and Principal Accounting Officer
Ms. Nemec joined Bolt Biotherapeutics in 2020, bringing over 20 years of experience as a senior finance leader in the life science industry. She is responsible for all aspects of the company's financial planning, accounting, and reporting. Ms. Nemec played a key role in Bolt's initial public offering and led activities to establish the company's financial management infrastructure, key reporting systems, and processes.
Grant Yonehiro, Chief Operating Officer
Mr. Yonehiro joined Bolt Biotherapeutics in 2016.
Michael N. Alonso, Ph.D., SVP, Research
Dr. Alonso serves as the Senior Vice President, Research at Bolt Biotherapeutics.
Nathan Ihle, Ph.D., SVP, Pharmaceutical Operations
Dr. Ihle joined Bolt Biotherapeutics in 2019, bringing nearly 30 years of experience in pharmaceutical research and development.
AI Analysis | Feedback
Key Risks to Bolt Biotherapeutics (BOLT)
- Clinical Development and Regulatory Approval Risk: Bolt Biotherapeutics faces significant risk related to the successful clinical development and regulatory approval of its drug candidates. The company recently discontinued its lead cancer drug, trastuzumab imbotolimod (BDC-1001), after determining it would not meet the criteria for continued development. This strategic pivot has shifted focus to earlier-stage, inherently higher-risk programs such as BDC-3042 and BDC-4182, described by analysts as being "at the high end of risk" due to their novelty and early developmental stage. Furthermore, there have been delays in the anticipated readout of initial clinical data for BDC-4182, now expected in the third quarter of 2026, pushing back its development timeline. The success of these candidates in clinical trials and their ability to gain regulatory approval are critical for the company's future prospects.
- Financial Position and Need for Additional Capital: Bolt Biotherapeutics has a history of incurring significant losses and expects this trend to continue for the foreseeable future. The company has undertaken drastic measures, including two rounds of approximately 50% workforce reductions in two years, to conserve capital and extend its cash runway. Despite these efforts, the company is "quickly burning through its resources," with negative free cash flow. Maintaining sufficient financial resources and the ability to raise additional capital on favorable terms are ongoing challenges crucial for the company's operations and continued research and development.
- Platform Technology Risk: The company's core proprietary Boltbodyâ„¢ ISAC (immune-stimulating antibody conjugate) platform technology, while seen as promising, carries inherent risks associated with novel drug platforms. The discontinuation of a previous lead program, BDC-2034, due to "off-target toxicity" illustrates the technical complexities and challenges in developing ISACs. Analysts have noted that immunostimulatory antibody-drug conjugation (ISAC) is a "difficult drug platform," requiring extensive product iteration and back-translation in its nascent stage of development. This indicates that despite the platform's potential, there is a risk of unexpected challenges and setbacks in developing new drug candidates using this technology.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Bolt Biotherapeutics' main products, which are focused on cancer immunotherapies for solid tumors, can be described by the following global market sizes:
- The Global Cancer Immunotherapy Market was valued between approximately USD 129.5 billion and USD 226.38 billion in 2024. It is projected to reach approximately USD 271.2 billion by 2033 and USD 443.17 billion by 2030, with some estimates going as high as USD 370 billion by 2033 and USD 338.40 billion by 2034. This market is expanding at a Compound Annual Growth Rate (CAGR) ranging from 8.6% to 17.5% over various forecast periods.
- The Global Solid Tumor Market was valued between approximately USD 360 billion and USD 362.21 billion in 2024. It is anticipated to reach between approximately USD 1,557.42 billion and USD 1,817 billion by 2032-2033, growing at a CAGR of around 19.7% to 20.00% during the forecast periods. Other estimates place the market at USD 375.4 billion by 2034 and USD 406.4 billion across the top 7 markets (US, EU4, UK, and Japan) by 2035.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Bolt Biotherapeutics (BOLT) over the next 2-3 years:- Commercialization and Expansion of the Vegan Silk Technology Platform: Bolt Biotherapeutics is strategically pivoting towards its proprietary Vegan Silk Technology Platform, which is projected to be a significant revenue driver. This platform is expected to see growth through new customer acquisitions in skincare and haircare, sustained reorder momentum from existing successful product launches, and the scalability of its supply chain to capture a larger share of the clean beauty market. Full-year 2025 revenue projections for this platform are estimated at $4.5 million, potentially doubling to $9.0 million by 2026.
- Advancement and Potential Collaborations for BDC-3042: The company is prioritizing its proprietary cancer immunotherapy program, BDC-3042, a next-generation Immune-Stimulating Antibody Conjugate (ISAC). Continued progress in its Phase 1 dose escalation trial and the achievement of clinical milestones are crucial. Success in these clinical developments could lead to future collaboration agreements and partnership revenue.
- Initiation and Clinical Progress of BDC-4182: Bolt Biotherapeutics plans to initiate clinical trials for BDC-4182, another next-generation ISAC targeting Claudin 18.2, in the second quarter of 2025. This program is seen as a key component of their refined pipeline. Successful clinical development and positive data from BDC-4182 could unlock future milestone payments from partnerships or lead to direct commercialization opportunities.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases made or authorized by Bolt Biotherapeutics in the last 3-5 years.
Share Issuance
- Bolt Biotherapeutics raised $150 million through an Initial Public Offering (IPO) in February 2021, issuing 8,800,000 shares at a price between $16.00 and $18.00 per share.
- In July 2020, the company completed an oversubscribed Series C financing round, raising $93.5 million.
- A 1-for-20 reverse stock split was effected on June 9, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
Inbound Investments
- In July 2020, Bolt Biotherapeutics closed a $93.5 million Series C funding round led by Sofinnova Investments, with participation from RA Capital Management, Surveyor Capital, Rock Springs Capital, and Samsara BioCapital.
- The company entered into a License and Collaboration Agreement with Genmab in May 2021 to discover and develop next-generation bispecific ISACs, with Bolt eligible to receive potential milestone payments of up to $285.0 million per therapeutic candidate.
- An oncology research and development collaboration with Innovent Biologics, Inc. was established in August 2021 and amended in March 2024, granting Bolt worldwide rights to two ISAC programs.
Outbound Investments
No information available regarding strategic outbound investments made by Bolt Biotherapeutics in other companies in the last 3-5 years.
Capital Expenditures
- Bolt Biotherapeutics anticipates its existing cash resources will fund operations and achieve key program milestones into the second half of 2026.
- A restructuring plan implemented in October 2025, including a 50% workforce reduction, is expected to extend the cash runway into 2027.
- The primary focus of capital allocation is on advancing clinical development programs, particularly BDC-3042 and BDC-4182, and supporting ISAC collaborations.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Bolt Biotherapeutics Earnings Notes | 12/16/2025 | |
| Bolt Biotherapeutics Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.52 |
| Mkt Cap | 0.3 |
| Rev LTM | 116 |
| Op Inc LTM | -92 |
| FCF LTM | -99 |
| FCF 3Y Avg | -72 |
| CFO LTM | -98 |
| CFO 3Y Avg | -70 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -3.5% |
| Rev Chg 3Y Avg | 12.8% |
| Rev Chg Q | 8.4% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Mgn LTM | -109.7% |
| Op Mgn 3Y Avg | -120.4% |
| QoQ Delta Op Mgn LTM | 8.5% |
| CFO/Rev LTM | -152.2% |
| CFO/Rev 3Y Avg | -111.2% |
| FCF/Rev LTM | -153.3% |
| FCF/Rev 3Y Avg | -112.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 4.2 |
| P/EBIT | -1.2 |
| P/E | -1.0 |
| P/CFO | -0.6 |
| Total Yield | -50.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -65.5% |
| D/E | 0.2 |
| Net D/E | -0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.8% |
| 3M Rtn | 18.0% |
| 6M Rtn | 30.0% |
| 12M Rtn | 19.8% |
| 3Y Rtn | -37.6% |
| 1M Excs Rtn | 3.1% |
| 3M Excs Rtn | 16.7% |
| 6M Excs Rtn | 22.7% |
| 12M Excs Rtn | 13.7% |
| 3Y Excs Rtn | -105.2% |
Price Behavior
Price Behavior
| Market Price | $4.95 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/05/2021 | |
| Distance from 52W High | -51.5% | |
| 50 Days | 200 Days | |
| DMA Price | $5.73 | $5.72 |
| DMA Trend | down | up |
| Distance from DMA | -13.6% | -13.5% |
| 3M | 1YR | |
| Volatility | 68.4% | 70.0% |
| Downside Capture | 177.65 | 143.89 |
| Upside Capture | 209.43 | 53.06 |
| Correlation (SPY) | 19.7% | 29.8% |
BOLT Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.20 | 1.02 | 1.37 | 1.11 | 1.03 | 0.90 |
| Up Beta | -6.55 | -5.02 | 1.82 | 2.34 | 1.04 | 0.78 |
| Down Beta | -1.47 | 0.51 | 0.30 | 1.03 | 1.20 | 1.47 |
| Up Capture | 611% | 372% | 189% | 73% | 39% | 7% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 23 | 31 | 63 | 117 | 333 |
| Down Capture | 510% | 178% | 168% | 86% | 114% | 102% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 18 | 30 | 61 | 130 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BOLT | |
|---|---|---|---|---|
| BOLT | -48.3% | 69.9% | -0.66 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 27.3% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 30.0% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | 7.6% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 17.5% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 21.4% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 26.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BOLT | |
|---|---|---|---|---|
| BOLT | -62.3% | 75.0% | -0.94 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 17.1% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 20.2% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 3.5% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 1.4% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 13.8% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BOLT | |
|---|---|---|---|---|
| BOLT | -38.5% | 75.0% | -0.94 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 17.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 20.3% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.5% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 1.4% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 13.8% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | 0.2% | -0.2% | 14.9% |
| 8/14/2025 | -5.3% | -10.1% | -2.2% |
| 3/24/2025 | -4.0% | -8.6% | -15.0% |
| 11/12/2024 | -3.9% | -12.6% | -17.6% |
| 8/13/2024 | -1.4% | -1.5% | -11.7% |
| 3/21/2024 | 3.4% | 20.7% | -4.3% |
| 11/9/2023 | -1.0% | -3.1% | -7.1% |
| 8/7/2023 | 0.8% | -3.9% | -14.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 5 | 4 |
| # Negative | 9 | 10 | 11 |
| Median Positive | 3.3% | 4.0% | 8.4% |
| Median Negative | -4.0% | -9.4% | -15.0% |
| Max Positive | 12.5% | 20.7% | 32.0% |
| Max Negative | -6.3% | -28.1% | -60.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/24/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nemec, Sarah | Senior VP, Finance and PAO | Direct | Buy | 10242025 | 5.49 | 125 | 686 | 5,179 | Form |
| 2 | Quinn, William P | President, CEO and CFO | Direct | Buy | 10242025 | 5.49 | 125 | 686 | 12,016 | Form |
| 3 | Nemec, Sarah | Senior VP, Finance and PAO | Direct | Buy | 5012025 | 0.50 | 2,500 | 1,241 | 8,258 | Form |
| 4 | Nemec, Sarah | Senior VP, Finance and PAO | Direct | Buy | 5012025 | 0.64 | 2,500 | 1,594 | 8,836 | Form |
| 5 | Quinn, William P | President, CEO and CFO | Direct | Buy | 5012025 | 0.50 | 2,500 | 1,241 | 20,492 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.